Premium
Atenolol in the treatment of essential hypertension during pregnancy.
Author(s) -
Rubin PC,
Butters L,
Low RA,
Reid JL
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb01974.x
Subject(s) - atenolol , essential hypertension , medicine , pregnancy , hypertension in pregnancy , adrenergic beta antagonists , preeclampsia , obstetrics , pharmacology , blood pressure , propranolol , biology , genetics
Atenolol has been studied prospectively in the management of ten patients with essential hypertension during pregnancy. Median supine BP fell significantly from 156/98 mmHg before treatment to 128/82 mmHg at term. Atenolol did not suppress cardiotocographic signs of foetal distress. Although there was one intrauterine death, the remaining nine babies had a median Apgar score at birth of 9 and a median weight which was 82% of the gestational mean. There were no cases of neonatal bradycardia or respiratory depression and the only case of hypoglycaemia was in a dysmature baby. These findings justify a formal study of beta‐adrenoceptor blocker therapy in hypertensive diseases of pregnancy.